KALA BIO, Inc. (LON:0JQ2)
London · Delayed Price · Currency is GBP · Price in USD 0.3850
-0.0052 (-1.33%)
Feb 12, 2026, 3:16 PM GMT
KALA BIO Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
7.53M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Futura Medical | 7.93M |
| IXICO | 6.53M |
| RUA Life Sciences | 4.11M |
| GENinCode | 2.91M |
KALA BIO News
- 5 weeks ago - KALA BIO Settles Approximately $10.6 million of Debt - GlobeNewsWire
- 2 months ago - KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
- 6 months ago - Kala Bio (KALA) Q2 Loss Widens 15% - The Motley Fool
- 6 months ago - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 7 months ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire
- 9 months ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire